Biomirra Biogenics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.44 M
as on 17-07-2024
- Company Age 19 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.52 Cr
as on 17-07-2024
- Revenue 15.34%
(FY 2023)
- Profit 12.68%
(FY 2023)
- Ebitda 38.80%
(FY 2023)
- Net Worth 14.44%
(FY 2023)
- Total Assets -1.33%
(FY 2023)
About Biomirra Biogenics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.44 M.
The company currently has active open charges totaling ₹1.52 Cr.
Rakesh Das, George Eayo, Spinaly Job, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232KL2005PTC018171
- Company No.
018171
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 May 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Calicut, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Biomirra Biogenics?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Das  | Director | 05-May-2005 | Current |
| George Eayo | Director | 05-May-2005 | Current |
| Spinaly Job | Director | 05-May-2005 | Current |
| Sajeesh Keloth | Director | 29-Sep-2007 | Current |
| Retnakaran Sreekumar | Director | 12-Jan-2022 | Current |
Financial Performance of Biomirra Biogenics.
Biomirra Biogenics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.34% increase. The company also saw a substantial improvement in profitability, with a 12.68% increase in profit. The company's net worth Soared by an impressive increase of 14.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biomirra Biogenics?
In 2023, Biomirra Biogenics had a promoter holding of 79.39% and a public holding of 20.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 29 Aug 2022 | ₹2.01 M | Open |
Hdfc Bank Limited Creation Date: 10 Aug 2022 | ₹0.96 M | Open |
Hdfc Bank Limited Creation Date: 25 Aug 2009 | ₹1.22 Cr | Open |
How Many Employees Work at Biomirra Biogenics?
Biomirra Biogenics has a workforce of 29 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biomirra Biogenics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biomirra Biogenics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
